GI Cancers

Frontline NALIRIFOX Regimen Demonstrates Promising Activity in Advanced PDAC

July 02, 2020

Long-term follow-up results from the study were presented in a poster at the virtual 2020 European Society of Medical Oncology World Congress on Gastrointestinal Cancer meeting.

Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors

July 01, 2020

Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.

FDA Grants Orphan Drug Designation to Novel Monoclonal Antibody in Pancreatic Cancer

June 30, 2020

"The Orphan Drug Designation we received from the FDA is of significant importance in accelerating the development of PBP1510 to provide better treatment for pancreatic cancer."

Analyzing the ESPAC-5F Trial in Borderline Resectable Pancreatic Cancer

June 30, 2020

Shubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.

Liposomal Irinotecan Combo Granted FDA Fast Track Designation for Advanced PDAC

June 17, 2020

A liposomal irinotecan combination was granted FDA Fast Track designation for the treatment of untreated and unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma.

CD40 Agonist Plus Chemotherapy Hypothesized to Improve Outcomes in Metastatic PDAC

June 16, 2020

In an interview with Targeted Oncology, Andrew L. Coveler, MD, discussed the phase 1 trial study of SEA-CD40 combined with a chemotherapy regimen, which he recently presented during the ASCO Virtual Scientific Program.

FDA Grants Orphan Drug Designation to DKN-01 for Gastric/GEJ Cancer

June 12, 2020

"We believe DKN-01 has the potential to be an important new therapy for this patient population that remains an area of high unmet medical need."

FDA Approves Nivolumab for Unresectable Esophageal Squamous Cell Carcinoma

June 11, 2020

The FDA granted approval to nivolumab for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma after receiving prior fluoropyrimidine- and platinum-based chemotherapy.

Margetuximab Gains FDA Orphan Drug Designation in Gastric/GEJ Cancer

June 05, 2020

The FDA has granted margetuximab an orphan drug designation for the treatment of patients with gastric and gastroesophageal junction cancer.

Significant Disease Control Achieved With Nivolumab/Temozolomide Combo in Neuroendocrine Tumors

May 27, 2020

“Although these are early data, we are encouraged by these findings. The depth of response is particularly impressive in some patients."